The recent discovery and accessibility of MR1-binding and MAIT-activating ligands has led to research into potential approaches targeting MAIT cells for both therapeutic and prophylactic treatments and vaccines against cancer [44, 52, 53], viruses [48], and bacteria [39–42, 45, 54]. Here, MR1 is linked to cancer.